Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – Q1 2020

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2020” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2020. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

1. Table of Contents 2

1.1. List of Tables 5

1.2. List of Figures 7

2. Deals in Pharmaceutical & Healthcare Industry Increased in Q1 2020 9

2.1. Pharmaceuticals & Healthcare, Deal Summary, Q1 2020 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2020 13

3.1. Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2020 13

3.2. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2020 15

3.3. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2020 16

3.4. Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2020 17

3.4.1. Thermo Fisher Scientific to Acquire Qiagen 17

3.4.2. Novartis Prices Public Offering of Notes for USD5 Billion 18

3.4.3. Amgen Raises USD5 Billion in Debt Offering of Senior Unsecured Notes 18

3.4.4. Gilead Sciences Acquires Forty Seven 18

3.4.5. Silence Therapeutics Enters into Collaboration with Astrazeneca 19

4. Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 20

4.1. Pharmaceuticals & Healthcare, Global, M&A, Q1 2020 20

4.1.1. Top M&A Deals in Q1 2020 21

4.1.3. Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2019 – Q1 2020 22

4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2020 23

4.2.1. Top Initial Public Offerings in Q1 2020 24

4.2.2. Top Secondary Offerings in Q1 2020 24

4.2.3. Top PIPE Deals in Q1 2020 25

4.2.4. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2019 – Q1 2020 26

4.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2020 27

4.3.1. Top Venture Financing Deals in Q1 2020 28

4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2020 29

4.3.4. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2020 31

4.3.6. Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2019 – Q1 2020 32

4.3.7. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2019 – Q1 2020 33

4.3.8. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2019 – Q1 2020 34

4.5. Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2020 35

4.5.1. Top Private Equity Deals in Q1 2020 36

4.5.2. Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2019 – Q1 2020 37

5. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2020 38

5.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2020 38

5.2. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2019 – Q1 2020 39

5.3. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2020 41

5.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2020 42

5.3.2. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2020 42

5.3.3. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2020 43

5.5. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 44

5.6. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2019 – Q1 2020 46

5.7. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2019 – Q1 2020 47

5.8. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 48

6. Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2020 50

6.1. Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2020 50

6.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 51

6.2.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2020 52

6.2.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2020 52

6.2.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2020 53

6.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2019 – Q1 2020 54

6.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2019 – Q1 2020 55

6.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deals, Q1 2019 – Q1 2020 57

6.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2019 – Q1 2020 58

6.7. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2019 – Q1 2020 60

7. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 62

7.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2020 62

7.1.1. Oncology – Deals of the Quarter 63

7.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2020 66

7.2.1. Central Nervous System – Deals of the Quarter 67

7.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2020 69

7.3.1. Infectious Disease – Deals of the Quarter 70

7.4. Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2020 72

7.4.1. Immunology – Deals of the Quarter 73

7.5. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2020 75

7.5.1. Metabolic Disorders – Deals of the Quarter 76

7.6. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2020 78

7.6.1. Cardiovascular – Deals of the Quarter 79

7.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2020 81

7.7.1. Gastrointestinal – Deals of the Quarter 82

7.8. Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2020 83

7.8.1. Dermatology – Deals of the Quarter 84

7.9. Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2020 86

7.9.1. Respiratory – Deals of the Quarter 87

7.10. Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2020 88

7.10.1. Ophthalmology – Deals of the Quarter 89

8. Deal Summary by Geography 91

8.1. Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2020 91

8.1.1. North America – Deals of the Quarter 92

8.2. Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2020 94

8.2.1. Europe – Deals of the Quarter 95

8.3. Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2020 97

8.3.1. Asia-Pacific – Deals of the Quarter 98

8.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2020 100

8.4.1. Rest of the World – Deals of the Quarter 101

9. Pharmaceuticals & Healthcare, Global, Top Advisors 103

9.1. Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2019 – Q1 2020 103

9.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2019 – Q1 2020 105

10. Further Information 107

10.1. Methodology 107

10.2. About GlobalData 107

10.3. Contact Us 108

10.4. Disclosure information 108

10.5. Disclaimer 108

List of Tables

1.1. List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 14

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2020 16

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2020 17

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2020 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2019 – Q1 2020 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2020 24

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2020 24

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2020 25

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 26

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 28

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2020 28

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2020 31

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 32

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 33

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2019 – Q1 2020 34

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 35

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2020 36

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 37

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 39

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 40

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 41

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2020 42

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2020 42

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2020 43

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2019 – Q1 2020 45

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2019 – Q1 2020 47

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2019 – Q1 2020 49

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 50

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 51

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2020 52

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2020 52

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2020 53

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 54

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2019 – Q1 2020 56

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Q1 2019 – Q1 2020 59

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2019 – Q1 2020 61

Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 63

Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 67

Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 70

Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 73

Table 43:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 76

Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 79

Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 82

Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 84

Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 87

Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 89

Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 92

Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 95

Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 98

Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 101

Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 104

Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 106

List of Figures

1.2. List of Figures

Figure 1: Pharmaceuticals & Healthcare, Number Of Deals, Q1 2019 – Q1 2020 10

Figure 2: Pharmaceuticals & Healthcare, Licensing Deals By Payment Mode, Q1 2019 – Q1 2020 11

Figure 3: Pharmaceuticals & Healthcare, Number Of Deals by Markets, Q1 2020 11

Figure 4: Pharmaceuticals & Healthcare, Number Of Deals by Region, Q1 2020 12

Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 13

Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2020 15

Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2020 16

Figure 8: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 20

Figure 9: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2019 – Q1 2020 22

Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 23

Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q1 2019 – Q1 2020 26

Figure 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 27

Figure 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2020 29

Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2020 31

Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2019 – Q1 2020 32

Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 33

Figure 17: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 35

Figure 18: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2019 – Q1 2020 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 38

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 39

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2019 – Q1 2020 41

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2019 – Q1 2020 44

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2019 – Q1 2020 46

Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2019 – Q1 2020 47

Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2019 – Q1 2020 48

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 50

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 51

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 54

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 55

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2019 – Q1 2020 57

Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2019 – Q1 2020 58

Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 – Q1 2020 60

Figure 33: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 62

Figure 34: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 66

Figure 35: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 69

Figure 36: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 72

Figure 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 75

Figure 38: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 78

Figure 39: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 81

Figure 40: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 83

Figure 41: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 86

Figure 42: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 88

Figure 43: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 91

Figure 44: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 94

Figure 45: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 97

Figure 46: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 100

Figure 47: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 103

Figure 48: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2019 – Q1 2020 105

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports